#MSVirtual2020 – Cardiovascular Risk Factors Linked to Brain Shrinkage
In people with multiple sclerosis (MS) under age 50, the presence of cardiovascular risk factors is associated with a…
Articles by Marta Figueiredo, PhD
#MSVirtual2020 – Early Intensive DMT Use in RRMS Appears More Effective Than Escalation
Early use of high efficacy disease-modifying therapies (DMTs) is more effective than the traditional approach — that of an…
#MSVirtual2020 – Roche Launches Phase 3 Clinical Program to Test Fenebrutinib
Roche has launched a Phase 3 clinical trial program to evaluate fenebrutinib, its investigational oral BTK inhibitor,…
#MSVirtual2020 – Novartis to Present Latest Data on Kesimpta, Mayzent and Gilenya
Novartis will present the latest clinical data on three of its approved multiple sclerosis (MS) therapies —…
#MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show
Janssen Pharmaceuticals’ investigational oral therapy ponesimod is superior to Sanofi’s Aubagio (teriflunomide) in delaying disability progression…
COVID-19 Pandemic Had Minimal Emotional Impact in Progressive MS Patients, Survey Finds
While the COVID-19 pandemic had an impact on the psychological well-being of people with progressive forms of multiple sclerosis (MS),…
#MSVirtual2020 — No Evidence of Disease Activity Seen in Most RRMS Patients After Switching to Ocrevus, Data Show
Switching to Genentech’s Ocrevus (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of…
#MSVirtual2020 – Meeting Focus Is on Advances in MS Research, Diagnostics, and Technology
The upcoming MSVirtual2020 meeting, the largest international conference dedicated to multiple sclerosis (MS) research, will focus on advances and…
#MSVirtual2020 – Zeposia Still Prevents Relapses in Relapsing MS Patients After 3 Years, Trial Data Show
Zeposia (ozanimod) oral capsules continue to safely and effectively prevent relapses and disability progression in people with relapsing forms…
Migraine Present in 30% of MS Patients, Review Study Finds
Migraine occurs in one third of people with multiple sclerosis (MS) and is more common among American and…
Gut Bacteria Working in Concert May Promote MS, Early Study Suggests
Two specific bacteria present together in the gut led to more immune attacks on myelin and harsher symptoms in a…
Infection Risk Higher for Ocrevus Than Rituximab, But Cancer Risk Lower
Ocrevus (ocrelizumab), a second-generation anti-CD20 antibody, may be associated with a greater risk of infections. But it carries…
Cashew Molecule Promotes Remyelination, Halts Disease Progression in MS Mice
Anacardic acid, a compound found in cashew nuts, promoted myelin regeneration and eased neuronal damage and disability in two mouse…
Blocking Protein, Reelin, Seen to Protect Immune System From Inflammation
Lowering levels of a protein called reelin — which regulates how permeable blood vessels are to immune cells — reduced…
Breastfeeding Appears Safe While Being Treated for Postpartum Relapse
The corticosteroid methylprednisolone is detected at low, safe levels in the breast milk of women with multiple sclerosis (MS) during and…
Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds
Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod)…
Order Seen in Motor Skills Affected by MS, With Walking Taking First Hit
Walking abilities decline earlier and faster than arm and hand function in people recently diagnosed with multiple sclerosis (MS), particularly…
Healthy Diet May Lower Risk of Relapse After 1st Myelin Attack, Study Suggests
A “prudent” diet rich in fresh fruit, non-fried fish, whole grains, vegetables, and nuts may lower the likelihood of a…
Way of Identifying Neurons Essential to Walking, Other Abilities Found
Researchers developed a way of using machine learning to identify those cells most important for a given function or task,…
NeuroScientific Biopharmaceuticals’ Lead Candidate, EmtinB, Shows Promise in Preclinical Model of MS
NeuroScientific Biopharmaceuticals (NSB)’s lead candidate EmtinB induces significantly greater myelin regeneration in a cellular model of multiple sclerosis (MS) than…
Study: Mavenclad Shows Long-term Effectiveness at Preventing MS Relapses, Disease Progression
Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple…
Tecfidera Safe and Effective in Hispanic/Latino MS Patients, Real-world Data Show
Tecfidera (dimethyl fumarate) is as safe and effective in Hispanic/Latino multiple sclerosis (MS) patients as it is in their non-Hispanic and…
Experts Clarify Concepts of MS States to Improve Patient Care, Clinical Trials
An international committee of multiple sclerosis (MS) experts further clarified how guidelines, updated in 2013, should be used to…
Blood Factors Impair Metabolism of Blood-brain Barrier in MS, Study Suggests
Molecules in the blood of multiple sclerosis (MS) patients promote a pro-inflammatory state and impair the metabolism and integrity of…
Progressive MS Linked to Faster Retinal Atrophy, Study Shows
People with progressive forms of multiple sclerosis (MS) have faster and disease-modifying therapy (DMT)-resistant retinal atrophy (thinning), compared to…
Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests
Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity…
COVID-19 May Not Be Severe in MS Patients, Early Data from Italy Suggest
People with multiple sclerosis (MS) may not be at higher risk of developing a severe COVID-19 infection, according…
COVID-19 Infection Not Severe in PPMS Patient on Ocrevus, Case Report Finds
COVID-19 infection in a multiple sclerosis (MS) patient being treated with Ocrevus (ocrelizumab) — an immunosuppressive therapy…
‘Chaperone’ Protein’s Lack Tied to Myelin Injury, Autoimmune Disease in Mouse Study
The lack of a “chaperone” protein — called HLA-DO — that helps to protect the body against threats by presenting…
Researchers Shed Light on Anti-inflammatory Effects of Vitamin D Supplements in MS
Vitamin D supplements promote a shift toward an anti-inflammatory state in people with multiple sclerosis (MS) through an increase…